tiprankstipranks
Immunocore Bolsters Board and Strikes Deal with BBA Funds
Company Announcements

Immunocore Bolsters Board and Strikes Deal with BBA Funds

Immunocore Holdings (IMCR) has provided an update.

Immunocore Holdings plc appointed Mr. Ranjeev Krishana, a seasoned executive with a history at Baker Bros. Advisors and Pfizer, to its Board of Directors on May 28, 2024. Krishana brings extensive pharmaceutical and international market experience to the role and will serve until the 2025 annual shareholder meeting. Concurrent with his appointment, the company entered into a Registration Rights Agreement with the BBA Funds, granting them rights for resale registration of certain company securities. This agreement entails the company’s commitment to file necessary registration statements upon request and allows the BBA Funds limited opportunities for underwritten offerings to sell their shares, with the company covering related expenses and providing indemnification.

Learn more about IMCR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyImmunocore announces randomization of first patient in Phase 3 brenetafusp trial
TheFlyImmunocore presents KIMMTRAK clinical data at ASCO 2024
GlobeNewswireImmunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!